Centessa Pharmaceuticals plc (NASDAQ:CNTA) Receives $25.17 Average Price Target from Brokerages

Centessa Pharmaceuticals plc (NASDAQ:CNTA) has received a consensus rating of “Buy” from the six analysts that are presently covering the firm, Marketbeat reports. Six research analysts have rated the stock with a buy rating. The average 1-year price objective among brokers that have covered the stock in the last year is $25.17.

A number of research analysts recently weighed in on the stock. Jefferies Financial Group lifted their price objective on shares of Centessa Pharmaceuticals from $13.00 to $19.00 and gave the company a “buy” rating in a research note on Wednesday, September 11th. B. Riley initiated coverage on Centessa Pharmaceuticals in a research note on Thursday, September 19th. They issued a “buy” rating and a $33.00 target price on the stock. Morgan Stanley upgraded shares of Centessa Pharmaceuticals from an “equal weight” rating to an “overweight” rating and increased their price target for the company from $11.00 to $26.00 in a research report on Thursday, September 19th. Oppenheimer reiterated an “outperform” rating and issued a $14.00 price objective on shares of Centessa Pharmaceuticals in a report on Wednesday, August 14th. Finally, BMO Capital Markets lifted their target price on shares of Centessa Pharmaceuticals from $20.00 to $35.00 and gave the stock an “outperform” rating in a research note on Monday, September 16th.

Centessa Pharmaceuticals Stock Performance

CNTA stock opened at $17.50 on Friday. Centessa Pharmaceuticals has a 12-month low of $5.58 and a 12-month high of $18.74. The firm has a market cap of $1.98 billion, a PE ratio of -11.44 and a beta of 1.47. The business has a 50 day moving average of $15.87 and a 200-day moving average of $12.07. The company has a quick ratio of 13.29, a current ratio of 13.29 and a debt-to-equity ratio of 0.27.

Centessa Pharmaceuticals (NASDAQ:CNTA) last released its earnings results on Tuesday, November 12th. The company reported ($0.37) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.42) by $0.05. As a group, sell-side analysts expect that Centessa Pharmaceuticals will post -1.68 earnings per share for the current year.

Insider Transactions at Centessa Pharmaceuticals

In other Centessa Pharmaceuticals news, insider Gregory M. Weinhoff sold 12,198 shares of the stock in a transaction on Thursday, August 22nd. The stock was sold at an average price of $12.17, for a total value of $148,449.66. Following the completion of the transaction, the insider now owns 241,171 shares in the company, valued at approximately $2,935,051.07. This represents a 4.81 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Saurabh Saha sold 175,000 shares of the company’s stock in a transaction dated Tuesday, September 10th. The stock was sold at an average price of $16.52, for a total transaction of $2,891,000.00. Following the completion of the sale, the chief executive officer now directly owns 776,924 shares in the company, valued at $12,834,784.48. This represents a 18.38 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders sold 325,031 shares of company stock valued at $5,213,043. Corporate insiders own 11.59% of the company’s stock.

Institutional Trading of Centessa Pharmaceuticals

Several institutional investors have recently bought and sold shares of CNTA. Price T Rowe Associates Inc. MD increased its holdings in shares of Centessa Pharmaceuticals by 16.5% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 2,958,079 shares of the company’s stock worth $33,427,000 after purchasing an additional 418,615 shares in the last quarter. Nantahala Capital Management LLC purchased a new stake in shares of Centessa Pharmaceuticals during the second quarter valued at $4,064,000. Driehaus Capital Management LLC increased its holdings in Centessa Pharmaceuticals by 89.5% in the 2nd quarter. Driehaus Capital Management LLC now owns 2,092,011 shares of the company’s stock worth $18,891,000 after buying an additional 987,997 shares in the last quarter. First Light Asset Management LLC raised its position in Centessa Pharmaceuticals by 59.2% in the 2nd quarter. First Light Asset Management LLC now owns 4,780,560 shares of the company’s stock worth $43,168,000 after buying an additional 1,778,515 shares during the last quarter. Finally, Farallon Capital Management LLC lifted its stake in Centessa Pharmaceuticals by 438.0% during the 2nd quarter. Farallon Capital Management LLC now owns 1,996,000 shares of the company’s stock valued at $18,024,000 after acquiring an additional 1,625,000 shares during the period. 82.01% of the stock is owned by hedge funds and other institutional investors.

About Centessa Pharmaceuticals

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders.